# John M. Maris

Source: https://onco.cc/people/john-maris/  
OnCo record `john-maris` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Neuroblastoma geneticist whose lab found the ALK mutations and immunotherapy targets now in paediatric trials.

## Summary

John Maris led the discovery that ALK mutations drive familial and sporadic neuroblastoma, the first targetable oncogene in the disease, and genome-wide association studies of neuroblastoma susceptibility. His laboratory identified GPC2 and other cell-surface targets for paediatric immunotherapy and he co-leads the NCI Pediatric Immunotherapy Discovery and Development Network.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: paediatric; neuroblastoma; genomics
- Role: Giulio D'Angio Chair in Neuroblastoma Research, Children's Hospital of Philadelphia
- Specialisms: Neuroblastoma genomics; Paediatric oncology; Immunotherapy targets; Precision medicine

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/John_M._Maris
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Maris%20JM%5BAuthor%5D%20neuroblastoma

## Connected records

- cancers: [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)
- technologies: [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- targets: [ALK](https://onco.cc/targets/alk/)
- institutions: [Children's Hospital of Philadelphia](https://onco.cc/institutions/chop/)

---
JSON: https://onco.cc/api/v1/entities/john-maris.json